News
NRSNW
0.1451
-3.27%
-0.0049
NeuroSense secures Japan patent for PrimeC ALS drug formulation through 2042
PUBT · 21h ago
NeuroSense meets Health Canada on PrimeC regulatory pathway for ALS drug submission
PUBT · 1d ago
Weekly Report: what happened at NRSNW last week (0601-0605)?
Weekly Report · 2d ago
Weekly Report: what happened at NRSNW last week (0525-0529)?
Weekly Report · 06/01 10:06
Weekly Report: what happened at NRSNW last week (0518-0522)?
Weekly Report · 05/25 10:09
Weekly Report: what happened at NRSNW last week (0511-0515)?
Weekly Report · 05/18 10:09
Weekly Report: what happened at NRSNW last week (0504-0508)?
Weekly Report · 05/11 10:07
Weekly Report: what happened at NRSNW last week (0427-0501)?
Weekly Report · 05/04 10:05
NeuroSense prices $600,000 private placement at $0.8 per share
PUBT · 04/28 18:30
Weekly Report: what happened at NRSNW last week (0420-0424)?
Weekly Report · 04/27 10:07
NeuroSense CMO Ferenc Tracik steps down, effective April 27
PUBT · 04/24 13:20
Weekly Report: what happened at NRSNW last week (0413-0417)?
Weekly Report · 04/20 10:03
Weekly Report: what happened at NRSNW last week (0406-0410)?
Weekly Report · 04/13 10:07
NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042
Reuters · 04/06 13:20
Weekly Report: what happened at NRSNW last week (0330-0403)?
Weekly Report · 04/06 10:07
NeuroSense Therapeutics receives Nasdaq notices over listing requirements
Seeking Alpha · 04/03 14:54
NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement
Reuters · 04/03 14:03
NeuroSense files Form 3 as CFO Or Eisenberg reports beneficial ownership
Reuters · 04/01 20:25
NeuroSense Therapeutics director Revital Mandil-Levin files initial beneficial ownership statement
Reuters · 03/31 20:28
Israel's NeuroSense Therapeutics 2025 net loss widens as expenses rise
Reuters · 03/31 13:31
More
Webull provides a variety of real-time NRSNW stock news. You can receive the latest news about Neurosense Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NRSNW
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease